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E-mail: gabriele.thumann@hcuge.chNeovascular age-related macular degeneration (nvAMD) is
characterized by choroidal blood vessels growing into the sub-
retinal space, leading to retinal pigment epithelial (RPE) cell
degeneration and vision loss. Vessel growth results from an
imbalance of pro-angiogenic (e.g., vascular endothelial growth
factor [VEGF]) and anti-angiogenic factors (e.g., pigment
epithelium-derived factor [PEDF]). Current treatment using
intravitreal injections of anti-VEGF antibodies improves vision
in about 30% of patients but may be accompanied by side
effects and non-compliance. To avoid the difficulties posed
by frequent intravitreal injections, we have proposed the trans-
plantation of pigment epithelial cells modified to overexpress
human PEDF. Stable transgene integration and expression is
ensured by the hyperactive Sleeping Beauty transposon system
delivered by pFAR4 miniplasmids, which have a backbone free
of antibiotic resistance markers. We demonstrated efficient
expression of the PEDF gene and an optimized PEDF cDNA
sequence in as few as 5  103 primary cells. At 3 weeks post-
transfection, PEDF secretion was significantly elevated and
long-term follow-up indicated a more stable secretion by cells
transfected with the optimized PEDF transgene. Analysis of
transgene insertion sites in human RPE cells showed an almost
random genomic distribution. The results represent an impor-
tant contribution toward a clinical trial aiming at a non-viral
gene therapy of nvAMD.
INTRODUCTION
Age-related macular degeneration (AMD) is the most common cause
of severe vision loss in patients over the age of 60. There are twomajor
forms of AMD, a non-neovascular or atrophic and a neovascular
form. The neovascular form (nvAMD) is characterized by the forma-
tion of subretinal choroidal neovascularization (CNV) and is the
major cause of severe vision loss in developed countries. It has been
estimated that approximately 23.5 million people worldwide are302 Molecular Therapy: Nucleic Acids Vol. 6 March 2017 ª 2017 The Aut
This is an open access article under the CC BY-NC-ND license (http://affected with AMD.1 Globally, it is the fourth most common cause
of blindness after cataracts, preterm birth, and glaucoma.2 AMD
affects about 0.4% of people between the ages of 50 and 60 years
and increases to about 12% of people over the age of 80 years.3
Evidence that in nvAMD overexpression of vascular endothelial
growth factor (VEGF) and decrease in the expression of pigment
epithelium-derived factor (PEDF) trigger the growth of choroidal
blood vessels into the subretinal space4,5 led to the development of
anti-angiogenic therapies for nvAMD. With the introduction of
anti-VEGF antibody therapy in 2006, andmore recently the introduc-
tion of the recombinant fusion protein aflibercept,6 about 30%–40%
of nvAMD patients regain three or more lines of visual acuity with
stabilization occurring in 90% of the remaining patients. However,
in addition to the fact that the majority of nvAMD patients do not
regain vision with anti-VEGF therapy, the frequent, often monthly,
intravitreal injections are a significant impediment to compliance,
considering that these patients are old and visually impaired. Further-
more, these treatments represent a significant economic burden to
healthcare systems.
A desirable alternative to overcome the difficulties associated with
frequent, lifelong intravitreal injections would be a treatment modal-
ity that introduces an inhibitor of neovascularization to the retina,
which would last for the life of the patient. To meet such treatment
modality, in 2006, Campochiaro and colleagues delivered the gene en-
coding PEDF to the retina of nvAMD patients using adenoviral (Ad)
delivery and reported significant improvement in 25% of patientshor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.orgafter 12 weeks and no harmful side effects.7,8 However, no follow-
up to the trial has been reported. Currently, three additional gene
therapy clinical trials are ongoing (https://clinicaltrials.gov/): trial
NCT01494805 is based on the use of an adeno-associated viral
(AAV) vector encoding sFlt-1, a splice variant of VEGF receptor 1;
trials NCT01301443 and NCT01678872 are based on the use of a len-
tiviral vector expressing endostatin and angiostatin (RetinoStat).
Aside from the results reported by Campochiaro et al.,8 the only other
available data are from two Association for Research in Vision and
Ophthalmology abstracts in 2014 and 2016 (M. Davies et al., 2014,
Invest. Ophthalmol. Vis. Sci., abstract; A.K. Lauer et al., 2016, Invest.
Ophthalmol. Vis. Sci., abstract) in which substantial transgene
expression as well as a safe and well-tolerated treatment exhibiting
signs of clinical benefit were reported for RetinoStat.
Even though efficient, the use of viral vectors to deliver genetic infor-
mation is problematic. Transgene delivery via non-integrating viral
vectors, such as Ad and AAV vectors, is episomal, often necessitating
re-administration, which can elicit an immune response leading to a
decline in transgene expression.9,10 However, several clinical trials
for Leber congenital amaurosis (LCA) showed that the AAV-based
subretinal delivery of the human RPE65 gene is effective and
safe.11 Lentiviral and retroviral vectors integrate the transgene into
the host cell’s genome and could possibly express the transgene for
the life of the host cells. However, the preference of lentiviral and
retroviral vectors to integrate into transcriptionally active genomic
regions is associated with a high risk of vector-associated insertional
mutagenesis, which could be harmful to the host cell and to the
patient.12–19
In nvAMD, choroidal blood vessel growth into the subretinal space
disrupts the normal architecture of the retina, leading to retinal
pigment epithelial (RPE) cell degeneration and vision loss. The use
of vectors to deliver an inhibitor of neovascularization into the subre-
tinal space of nvAMDpatients will benefit those patients, in which the
RPE cells retain normal function. However, in nvAMD patients, RPE
cells degenerate rapidly.20 Regain of vision in most nvAMD patients
will require not only the expression of an inhibitor of neovasculariza-
tion, but more importantly a functional retinal pigment epithelium. It
has previously been shown that transplantation of RPE or iris
pigment epithelial (IPE) cells, as a substitute for RPE cells, to the sub-
retinal space did not result in vision improvement in nvAMD pa-
tients.21–23
We have postulated that the inhibition of CNV will require that the
transplanted cells overexpress PEDF, which would not only inhibit
neovascularization but also act as a neuroprotective agent for the
retina. The complication associated with viral vectors can be avoided
by the use of the non-viral Sleeping Beauty (SB) transposon system,
which provides efficient and stable gene transfer and transgene
expression, has a safer integration profile compared to other inte-
grating vectors24 and offers ease of production. In fact, we have
previously shown that the ARPE-19 cell line and primary bovine
pigment epithelial cells transfected ex vivo by electroporation witha PEDF-encoding SB transposon delivered as plasmid DNA express
elevated and stable levels of PEDF.25 Importantly, transplantation
of these cells in a rabbit model of corneal neovascularization sup-
pressed and reversed neovascularization.26 In these experiments, we
used the pT2-CMV-PEDF/EGFP plasmid, which is 7,258 bp in size.
The backbone contains an ampicillin resistance marker, and the
expression cassette is composed of a His-tagged human PEDF trans-
gene, an intervening sequence (IVS)/internal ribosomal entry site
(IRES) element, and the EGFP gene,25 making the plasmid unsuitable
for use in humans.
Although safer than viral vectors, the use of plasmids to deliver genes
for therapeutic use also displays some drawbacks. Specifically, effi-
cient production of plasmids in bacteria requires that the plasmid en-
codes a marker that favors the growth of the bacteria containing the
plasmid, generally an antibiotic resistance gene. However, the pres-
ence of antibiotic resistance markers in gene therapy vectors is a
matter of concern. Residues of antibiotics could contaminate the final
product, placing at risk patients with severe hypersensitivity to anti-
biotics, which is relatively common for b-lactam antibiotics.27
Furthermore, the removal of antibiotic resistance genes allows for a
reduction in the size of the plasmid vector, resulting in an increase
in transfection efficiency.28
Finally, careful design of not only vector sequences, but of the ther-
apeutic genes themselves can affect the outcome of somatic gene
transfer. Namely, transgenes are usually encoded by intronless
cDNA constructs, which, however, can still carry functionless exonic
splice enhancer (ESE) sequences. In intron-containing genes, rates of
evolution are lower near exon-intron boundaries than in exon
cores.29,30 Analysis of the rate of sequence evolution in retrogenes,
which are derived from intron-containing genes by retroposition
and may be considered as mimics of transgenes, led to the suggestion
that intronless genes might be under selection to avoid some or all
ESE motifs, as the genes might need to avoid attracting a splicing
machinery. Based on this proposition, it was suggested that intron-
less transgenes could be improved by directed modification at synon-
ymous sites of ESE motifs to degrade them while simultaneously
improving RNA stability. Recent evidence has suggested that in
intronless genes some ESE motifs remain under selection for
splice-independent functions, while recent retrogenes—the best
mimics of transgenes—evolved unusually fast at ESE motif sites,31
supporting the hypothesis that loss of some ESE motifs could be
beneficial. Here, we used an optimization strategy to decrease ESE
motifs in the PEDF coding sequence.
Since the ultimate goal of our research is to transplant RPE and/or IPE
cells transfected with the PEDF gene into the subretinal space of
nvAMD patients and to avoid the use of plasmids encoding antibiotic
resistance genes, we have developed a protocol for the efficient deliv-
ery of the PEDF gene encoded in plasmids free of antibiotic resistance
markers (pFAR) combined with the enhanced Sleeping Beauty
(SB100X) transposon system. Here, we report that SB100X-mediated
delivery of the PEDF gene, using pFAR4 miniplasmids to encode theMolecular Therapy: Nucleic Acids Vol. 6 March 2017 303
Table 1. Western Blot-Based Quantification of PEDF Secretion by PEDF-Transfected Bovine IPE and Human RPE Cells
Signal Intensities (Mean ± SD) pFAR-PEDF versus pFAR-PEDFo
1  104 bIPE cells Control 1.00 ± 0.03 (n = 19) Control 1.00 ± 0.00 (n = 9)
pFAR-PEDF 17.96 ± 35.28 (n = 211) *p = 0.0376 pFAR-PEDFo 8.84 ± 7.65 (n = 106) **p = 0.0028 **p = 0.0090
5  103 bIPE cells Control 1.00 ± 0.11 (n = 18) Control 1.00 ± 0.00 (n = 11)
pFAR-PEDF 5.25 ± 5.20 (n = 200) ***p = 0.0007 pFAR-PEDFo 8.42 ± 9.95 (n = 132) *p = 0.0149 ***p = 0.0002
1  104 hRPE cells Control 1.00 ± 0.18 (n = 52) Control 1.00 ± 0.17 (n = 26)
pFAR-PEDF 2.54 ± 0.99 (n = 312) ****p < 0.0001 pFAR-PEDFo 1.93 ± 0.76 (n = 156) ****p < 0.0001 ****p < 0.0001
5  103 hRPE cells Control 1.00 ± 0.13 (n = 48) Control 1.00 ± 0.19 (n = 26)
pFAR-PEDF 2.02 ± 1.09 (n = 288) ****p < 0.0001 pFAR-PEDFo 2.25 ± 1.14 (n = 156) ****p < 0.0001 *p = 0.0378
For each sample, one or two control transfections without the addition of miniplasmid DNA and ten to 12 transfections using 0.03 mg pFAR4-CMV SB100X SV40 transposase and
0.47 mg pFAR4-ITRs CMV PEDF BGH or pFAR4-ITRs CMV PEDFoptimized BGHminiplasmid DNA were carried out. Culture supernatants were analyzed for total PEDF secretion
21 days after transfection (Figures S2–S5). Signal intensities of PEDF-transfected and PEDFo-transfected cells were normalized to the signal intensities of control cells. Statistical
analysis showed a significant difference in secretion between PEDF-transfected and PEDFo-transfected cells.
Molecular Therapy: Nucleic AcidsPEDF gene and the SB100X transposase, is efficient and results in
stable, long-term gene expression and protein secretion in as few as
5  103 primary bovine IPE and human RPE cells.
RESULTS
Definition of the SB100X Transposase to PEDF Transposon
Ratio
We previously showed that ratios ranging from 0.038 mg SB100X
transposase expression plasmid DNA and 0.462 mg PEDF transposon
plasmid DNA (1+12) to 0.017 mg SB100X transposase and 0.483 mg
PEDF transposon (1+28) resulted in good transposition efficiencies,
as determined by the secretion of recombinant PEDF.25 Since trans-
fection experiments with varying amounts of pFAR4-CMV SB100X
SV40 transposase and pFAR4-ITRs CMV PEDF BGH (pFAR-
PEDF) transposon miniplasmid DNA exhibited similar results, with
the highest PEDF secretion rates observed for the ratios 1+16 and
1+20 (Figure S1), all subsequent experiments were carried out using
0.03 mg SB100X transposase expression plasmid DNA and 0.47 mg
PEDF transposon plasmid DNA.
Optimization of the PEDF DNA Sequence
Using the implemented algorithm, the number of ESE motifs in the
PEDF coding sequence was decreased from 135 to 55, and GC nucle-
otide content increased from 63.3% to 71.8%. This optimized
sequence is hereafter referred to as PEDFo.
SB100X-Mediated Transfection of Cultured Primary Bovine IPE
Cells with the PEDF Gene Delivered by the pFAR4 Miniplasmid
Western blot analysis 21 days after transfection showed approxi-
mately an 18-fold increase in the secretion of PEDF by 1 104 bovine
IPE cells transfected with the pFAR-PEDF transposon miniplasmid
and approximately a 9-fold increase by 1  104 cells transfected
with the pFAR-PEDFo transposon miniplasmid (Table 1; Figures
S2A and S3A) compared to non-transfected cells. Transfection of
5  103 bovine IPE cells showed a 5-fold increase in PEDF secretion
when transfected with the pFAR-PEDF transposon miniplasmid and
approximately an 8-fold increase when transfected with the pFAR-304 Molecular Therapy: Nucleic Acids Vol. 6 March 2017PEDFo transposon miniplasmid (Table 1; Figures S2B and S3B)
compared to non-transfected cells.
Endogenous and recombinant PEDF gene expression were analyzed
by real-time qPCR in bovine IPE cells cultured for 21 days after
transfection. PEDF gene expression was significantly increased after
transfection with the pFAR-PEDF and the pFAR-PEDFo transposon
miniplasmids compared to non-transfected cells (Figure 1). Endoge-
nous PEDF gene expression in non-transfected and transfected cells
did not show any significant differences. High gene expression levels
of recombinant PEDF were detected in 1  104 and 5  103-trans-
fected cells, but not in non-transfected cells. However, recombinant
PEDF expression in pFAR-PEDF-transfected cells was not signifi-
cantly different from recombinant PEDF expression in pFAR-
PEDFo-transfected cells (Figure 1).
At about 4 weeks post-transfection, quantification by ELISA showed
that 1  104 PEDF-transfected bovine IPE cells secreted into the me-
dia an average of 32.6 ± 25.5 versus 0.05 ± 0.09 ng for non-transfected
cells. Similarly, 1  104 PEDFo-transfected cells secreted an average
of 35.3 ± 25.8 versus 0.04 ± 0.07 ng for non-transfected cells (Fig-
ure 2A). When 5  103 cells were transfected, PEDF was secreted
at a concentration of 31.4 ± 24.9 ng for PEDF-transfected cells and
41.4 ± 41.6 ng for PEDFo-transfected cells. PEDF secretion of cells
transfected without miniplasmid DNA varied from 0.07 ± 0.17 to
0.03 ± 0.02 ng (Figure 2B). Levels of PEDF protein secreted by both
1  104 and 5  103 transfected cells were statistically different
from non-transfected cells, regardless of the miniplasmid transposon
used. However, the amount of PEDF secreted by cells transfected with
the optimized PEDF sequence was not significantly different from the
amount secreted by cells transfected with the native recombinant
PEDF sequence.
Long-term secretion of PEDF by cells transfected with the pFAR-
PEDF and the pFAR-PEDFo transposon miniplasmids was examined
by immunoblotting at regular intervals for 1 year. In almost all cases,
normalized PEDF signal intensities were significantly enhanced
Figure 1. PEDF Gene Expression in Primary Bovine
IPE Cells after SB100X-Mediated Transfection
For each IPE sample, control transfections without the
addition of miniplasmid DNA and transfections using
0.03 mg pFAR4-CMV SB100X SV40 transposase and
0.47 mg pFAR4-ITRs CMV PEDF BGH or pFAR4-ITRs
CMV PEDFoptimized BGH miniplasmid DNA were per-
formed. Total RNA was isolated 21 days after trans-
fection. PEDF gene expression by cells transfected
with pFAR-PEDF and pFAR-PEDFo was analyzed for (A)
1 104 cells for eight bovine eyes and (B) 5 103 cells for
ten bovine eyes. Statistical analysis using a Kruskal-Wallis
test showed a significant difference between transfected
cells and non-transfected control cells. No significant
difference was observed between cells transfected with
pFAR-PEDF and pFAR-PEDFo.
www.moleculartherapy.orgcompared to non-transfected cells, though they gradually decreased
with time. During the 1 year, mean normalized signal intensities
for 1  104 cells were reduced by 32.1% from 49 to 365 days post-
transfection for pFAR-PEDF-transfected cells and by 28.7% for
pFAR-PEDFo-transfected cells (Figure 3A; Table S1). For 5  103
cells, the mean band intensity decreased by 43.2% for PEDF-trans-
fected cells, whereas for PEDFo-transfected cells the decrease was
29.3% (Figure 3B; Table S1). However, analysis at each time period
revealed that the differences observed between PEDF secretion by
PEDF-transfected and PEDFo-transfected cells were not statistically
significant.
SB100X-Mediated Transfection of Cultured Primary Human RPE
Cells with the PEDF Gene Delivered by the pFAR4 Miniplasmid
Similar to the results of cultured bovine IPE cells, western blot anal-
ysis at 21 days after transfection showed a significant increase in the
secretion of PEDF by human RPE cells transfected with the pFAR-
PEDF transposon miniplasmid (Table 1; Figure S4) and the pFAR-
PEDFo transposon miniplasmid (Table 1; Figure S5) compared to
cells transfected without the addition of miniplasmid DNA. 1  104
cells transfected with the pFAR-PEDF transposon miniplasmid ex-
hibited 31.6% higher normalized PEDF signal intensities than cells
transfected with the pFAR-PEDFo transposon miniplasmid. For
5  103 cells, a 10.2% decrease in the mean band intensity for
PEDF-transfected cells was observed compared to PEDFo-transfected
cells (Table 1).
PEDF gene expression was analyzed by real-time qPCR in human
RPE cells cultured for 21 days after transfection (Figure 4). In all cases,
a significant increase in total PEDF gene expression was observed
compared to endogenous PEDF gene expression. Transfection of
1  104 (Figure 4A) and 5  103 (Figure 4B) cells resulted in higher
PEDF gene expression for pFAR-PEDF-transfected cells compared to
pFAR-PEDFo-transfected cells.
ELISA-based quantification of PEDF secretion corresponded to the
differences observed for PEDF gene expression. At 3 weeks post-
transfection, 1  104 cells PEDF-transfected cells secreted into the
media an average of 1.38 ± 1.42 versus 0.07 ± 0.07 ng for non-trans-fected control cells, whereas PEDFo-transfected cells secreted 1.02 ±
0.63 versus 0.06 ± 0.02 ng for non-transfected control cells (Fig-
ure 5A). When transfection was done with 5  103 cells, PEDF was
secreted at a concentration of 1.06 ± 0.82 ng for PEDF-transfected
cells and 0.89 ± 0.61 ng for PEDFo-transfected cells; PEDF secretion
by cells transfected without miniplasmid DNA varied from 0.06 ±
0.03 to 0.07 ± 0.03 ng (Figure 5B). Statistical analysis showed signif-
icant differences between PEDF secretion from transfected and non-
transfected cells. However, the amount of PEDF protein secreted by
cells transfected with the native PEDF sequence was not significantly
different than the amount secreted by cells transfected with the opti-
mized PEDF sequence.
Long-term secretion of PEDF was analyzed by immunoblotting for a
minimum of 6.5 months. The mean normalized signal intensity for
1  104 pFAR-PEDF-transfected cells was reduced by 59.0% from
31 to 215 days and by 24.6% for 1  104 pFAR-PEDFo-transfected
cells from 27 to 193 days (Figure 6A; Table S2). The mean intensity
decrease for 5  103 PEDF-transfected cells was 61.7% from day 33
to day 216. However, for 5  103 PEDFo-transfected cells, the
mean normalized signal intensities increased by 9.5% from day 31
to day 201 (Figure 6B; Table S2). No statistical difference was
observed between PEDF secretion by PEDF-transfected and
PEDFo-transfected cells for the first 3.5 months. However, at later
time periods, secretion by both 1  104 and 5  103 pFAR-PEDFo-
transfected cells was significantly higher than secretion by cells trans-
fected with pFAR-PEDF (Figure 6; Table S2).
Integration Profile of the pFAR4-ITRs CMV PEDF BGH
Transposon Plasmid into Human RPE Cells
To investigate the integration profile of the PEDF transposon into hu-
man RPE cells, 1  104 cells were transfected with 0.03 mg pFAR4-
CMV SB100X SV40 transposase and 0.47 mg pFAR4-ITRs CMV
PEDF BGH transposon. After 21 days, cultures were terminated
and genomic DNA extracted. Sequences neighboring the insertion
sites were PCR-amplified using transposon inverted repeat (IR)-spe-
cific primers, and the resulting libraries were subjected to Illumina
sequencing. Mapping the sequence reads on the human genome iden-
tified 3,114 unique transposon integration sites. As expected, theMolecular Therapy: Nucleic Acids Vol. 6 March 2017 305
Figure 2. ELISA Quantification of Total PEDF
Secreted by PEDF-Transfected Primary Bovine IPE
Cells
For each IPE sample, two control transfections without
the addition of miniplasmid DNA and two transfections
using 0.03 mg pFAR4-CMV SB100X SV40 transposase
and 0.47 mg pFAR4-ITRs CMV PEDF BGH or pFAR4-
ITRs CMV PEDFoptimized BGH miniplasmid DNA were
carried out. (A) PEDF secretion by 1  104 initially used
cells. Mean ± SD of 16 bovine eyes transfected with
pFAR-PEDF 27.5 ± 9.8 days after electroporation and
mean ± SD of eight bovine eyes transfected with pFAR-
PEDFo 24.0 ± 7.4 days after electroporation. (B) PEDF
secretion by 5  103 initially used cells. Mean ± SD of 15
bovine eyes transfected with pFAR-PEDF 28.5 ± 13.8 days after electroporation and mean ± SD of ten bovine eyes transfected with pFAR-PEDFo 27.1 ± 16.3 days after
electroporation. Total PEDF secretion of PEDF- and PEDFo-transfected cells was compared to the respective control cells (p < 0.0001, unpaired two-tailed t test) and total
PEDF secretion of PEDF-transfected cells was compared to total PEDF secretion of PEDFo-transfected cells (not significant for 1 104 cells and 5 103 cells, unpaired two-
tailed t test).
Molecular Therapy: Nucleic Acidsinsertions occurred preferentially at the central dinucleotides of
ATATATAT palindromic sequences (Figure 7A). To profile the
SB insertions on a genomic scale, we next determined the fre-
quencies of integrations into annotated genomic features including
30 UTRs, 50 UTRs, exons, introns, gene bodies, and regions around
transcription start sites of RefSeq genes. When comparing the inser-
tion profiles to a control set of 10,000 computationally generated
random human genomic loci, no apparent bias was detected for
any of the categories analyzed (Figure 7B). Furthermore, SB trans-
poson integrations occur in genomic safe harbors, defined by five
criteria32,33 (Figure 7C), at about 25% (Figure 7D). These results
are in good agreement with numerous previous studies, which
established a close-to-random insertion profile for the SB system
in human cells.34–37
DISCUSSION
The development of the pFAR plasmid has enabled the maintenance
and propagation of miniplasmids in the absence of antibiotics, elim-
inating a possible safety complication in the production of gene ther-
apeutic vectors for use in human clinical trials. Instead of antibiotic
selection, the propagation of the pFAR plasmid is based on the
suppression of a chromosomal nonsense mutation in the thyA
gene of the E. coli producer strain, ensuring efficient miniplasmid
amplification using commercially available thymidine and animal
components-free growth medium, which meets the requirements of
regulatory authorities. In addition, the removal of the antibiotic resis-
tance gene results in significant plasmid size reduction, which allows
for a more efficient transgene38,39 and SB transposon delivery
(C. Marie and S.J., unpublished data).
The hyperactive form of the SB transposon system, SB100X,40 merges
the advantages of viral vectors and non-viral plasmid DNA, since it
possesses integrative properties and can be introduced into the cells
by plasmid vectors, which reduces immunogenicity and simplifies
its manufacturing. The SB100X transposase meditates the stable
genomic integration of the expression cassette into the host cell’s
genome, which allows for long-term transgene expression. Effective306 Molecular Therapy: Nucleic Acids Vol. 6 March 2017SB-mediated gene transfer has been reported for various in vitro
and in vivo disease models,41–43 and it has been approved for clinical
application of genetically modified T cells to treat B-lymphoid malig-
nancies.44,45 We have reported long-term and continuous PEDF
secretion by RPE cells that were transfected with the PEDF transgene
using the SB100X transposon system25 and demonstrated that
the subretinal transplantation of PEDF-transfected cells in a rat
model of CNV reduces neovascularization and inhibits new vessel
formation.46
In animal studies, several gene therapeutic approaches for nvAMD
have been described in which the transgenes have been delivered
in vivo to resident cells by subretinal injection of viral vectors, and
a clinical trial in patients with nvAMD has indicated that delivery
of a gene to enhance the endogenous anti-angiogenic environment
is a feasible approach (reviewed by Campochiaro7 in 2011). However,
delivery of transgenes via viral vectors can distribute the transgene
into tissues adjacent to the tissue of interest.47 We have proposed to
treat nvAMD using a protocol comprising cell isolation from a
patient, ex vivo transfection of the cells with the PEDF transgene
using SB100X and subretinal transplantation of the transfected cells
to the subretinal space of the same patient within a single surgical ses-
sion lasting approximately 1 hr. Since the isolation of IPE or RPE cells
from a patient’s biopsy yields a limited number of cells, i.e., 5 103 to
1 104 cells, classical methodologies for non-viral or virally mediated
gene delivery are not suitable, since they require large numbers of
cells and the necessity of selecting stably transfected cells in vitro,
e.g., the generation of CD19-specific chimeric-antigen receptor
(CAR) T cells.48
Here, we report the development of a protocol for the efficient trans-
fection of as few as 5  103 primary pigment epithelial cells using
pFAR miniplasmids carrying the SB100X transposase and the PEDF
gene. IPE cells isolated from a number of bovine eyes and RPE cells
isolated from a number of human donor eyes and co-transfected
with both plasmids secrete high levels of PEDF continuously for the
approximately 6 months that the cells have been followed in culture.
Figure 3. Western-Blot-Based Quantification of
Long-Term PEDF Secretion in Primary Bovine IPE
Cells after SB100X-Mediated Transfection
For each IPE sample, two control transfections without
the addition of miniplasmid DNA and two transfections
using 0.03 mg pFAR4-CMV SB100X SV40 transposase
and 0.47 mg pFAR4-ITRs CMV PEDF BGH or pFAR4-
ITRs CMV PEDFoptimized BGH miniplasmid DNA were
carried out. Culture supernatants were analyzed for total
PEDF secretion 7, 15, 19, 32, and 52 weeks after trans-
fection. Western blot signal intensities of PEDF-trans-
fected and PEDFo-transfected cells were normalized to
the signal intensities of the control cells. Data are pre-
sented as mean ± SD. Mean signal intensities of PEDF
secretion 21 days after transfection are indicated by the
dashed line. For 365 ± 3 days, levels of PEDF secreted by
pFAR-PEDF- and pFAR-PEDFo-transfected cells were
analyzed for (A) 1  104 cells and (B) 5  103 cells. Sta-
tistical analysis using an unpaired two-tailed t test showed
a significant difference between transfected cells and
non-transfected control cells. No significant difference
was observed between cells transfected with pFAR-
PEDF and pFAR-PEDFo at any time period.
www.moleculartherapy.orgThe lower increase in PEDF secretion by PEDF-transfected primary
human cells than the secretion by primary bovine cells may be due
to the difference in the age of the human donors compared to the
young bovine animals as well as to the fact that human cells were ob-
tained from donor eyes 31.8 ± 13.7 hr postmortem whereas bovine
cells were obtained from eyes within 3 hr postmortem. The increase
in PEDF secretion by pFAR-PEDFo-transfected bovine IPE cells after
102 ± 9 (Figure 3A) and 103 ± 9 days (Figure 3B) suggests that the
transfected cells were still able to proliferate.
Most importantly, we did not observe transgene silencing, which
often occurs within a few days using the cytomegalovirus (CMV) pro-
moter,49,50 although the amount of PEDF secretion by the transfected
cells decreased gradually over time, which was likely the result of
the reduction of fetal bovine serum (FBS) in the cell-culture
medium from 10% to 1%, once the primary cell cultures reached
confluence.
To improve the stability of the human PEDF gene, the optimization
strategy implemented here intended to mimic natural transgenes,
removed potential ESE motifs by modulating synonymous sites and
also included modulation of AT versus GC nucleotide content. How-
ever, removal of the ESE motifs did not affect PEDF gene expression
significantly. In fact, analysis of the relative PEDF gene expression and
quantification of total PEDF protein secretion in human RPE cellsMolecula21 days after transfection revealed higher
expression and secretion levels by pFAR-
PEDF-transfected cells than in pFAR-PEDFo-
transfected cells. No statistical difference was
observed between PEDF secretion by PEDF-
transfected and PEDFo-transfected humanRPE cells for the first 3.5 months. However, at 5 and 7 months after
transfection, secretion by 1  104 and 5  103 pFAR-PEDFo-trans-
fected human RPE cells was significantly higher than secretion by
cells transfected with pFAR-PEDF, suggesting that the optimization
protocol improved stability.
In contrast to the genomic integration profile of retroviral systems
and other transposon systems (piggyBac and Tol2), which show
integration preferences for actively transcribed genes,51–53 SB-based
integration is random.37,54 Compared to computationally generated
control datasets, SB100X-mediated genomic integration of the
PEDF gene delivered by the pFAR4 vector into primary human
RPE cells showed a close-to-random profile. Noteworthy, the ratio
of integrations of the PEDF gene into exons, representing 4% of the
total integration events, was lower than the ratio expected by random
distribution. In human T cells, SB transposon insertions were shown
to have the lowest deviation from a random genome-wide distribu-
tion as well as the highest theoretical chance of targeting a safe site
of the genome.35,55 Although site-specific gene insertion into safe
harbor sites by designer nucleases, such as zinc finger nucleases,
TALENs, and the CRISPR/Cas system, is appealing from a safety
point of view, the overall efficiency of transgene integration in
polyclonal RPE cell populations by these technologies is expected to
be far lower than with our transposon-based approach. In contrast,
robust gene delivery in primary human cells by the hyperactiver Therapy: Nucleic Acids Vol. 6 March 2017 307
Figure 4. Relative PEDF Gene Expression in Primary
Human RPE Cells after SB100X-Mediated
Transfection
For each donor sample, four control transfections without
the addition of miniplasmid DNA and four transfections
using 0.03 mg pFAR4-CMV SB100X SV40 transposase
and 0.47 mg pFAR4-ITRs CMV PEDF BGH or pFAR4-
ITRs CMV PEDFoptimized BGH miniplasmid DNA were
performed. Total RNA was isolated 21 days after trans-
fection. Endogenous and total (endogenous + recombi-
nant) PEDF gene expression in PEDF-transfected and
PEDFo-transfected cells were related to the PEDF gene
expression in control cells, whose expression was set to 1
(dashed line). (A) For 1  104 cells, PEDF expression by
cells transfected with pFAR-PEDF was analyzed for 25
human donor eyes (age: 65.8 ± 14.2 years; gender: 12 males and 13 females; postmortem time: 32.4 ± 14.5 hr; cultivation time before transfection: 43.0 ± 15.7 days); PEDF
expression by cells transfected with pFAR-PEDFo was analyzed for 13 human donor eyes (age: 61.1 ± 16.3 years; gender: seven males and six females; postmortem time:
33.5 ± 16.2 hr; cultivation time before transfection: 39.8 ± 17.1 days). (B) For 5 103 cells, PEDF expression by cells transfected with pFAR-PEDFwas analyzed for 20 human
donor eyes (age: 63.7 ± 14.5 years; gender: 13 males and seven females; postmortem time: 34.6 ± 14.9 hr; cultivation time before transfection: 45.3 ± 16.5 days); PEDF
expression for cells transfected with pFAR-PEDFo was analyzed for 13 human donor eyes (age: 61.1 ± 16.3 years; gender: eight males and five females; postmortem time:
32.5 ± 16.1 hr; cultivation time before transfection: 42.6 ± 18.6 days). Data are presented as box-and-whisker plots (whiskers: min to max). Total PEDF gene expression was
compared to the endogenous PEDF gene expression (p < 0.0001, unpaired two-tailed t test) and total PEDF gene expression of PEDF-transfected cells was compared to
total PEDF gene expression of PEDFo-transfected cells (p = 0.0248 for 1  104 cells and p = 0.0161 for 5  103 cells, unpaired two-tailed t test).
Molecular Therapy: Nucleic AcidsSB100X transposase is matched by an attractive safety profile in the
context of currently available integrating gene vector systems.
Thus, using a transfection protocol that combines the use of the
SB100X transposase and the pFAR4miniplasmid, we have shown effi-
cient transgene delivery to as few as 5  103 primary cells, sustained
expression of the transgene, a close-to-random transgene integration
profile, without the potential integration of plasmid-encoded anti-
biotic resistance genes into the genome of the host cell. These results
are an important step of the TargetAMD project toward the approval
of a clinical trial, where the PEDF transgene is introduced into autol-
ogous pigment epithelial cells ex vivo, followed by the transplantation
to the subretinal space of nvAMD patients. Further deliverables that
comprise, for example, different animal studies to evaluate efficacy
and safety, the production of transfection-related agents under
good manufacturing practice (GMP) conditions as well as adminis-
trative work are already finished or currently in process.
MATERIALS AND METHODS
Miniplasmid Description
pFAR4 is a miniplasmid vector devoid of antibiotic resistance
markers. Its propagation relies on the suppression by a suppressor
t-RNA, encoded in the pFAR4 miniplasmid, of an amber mutation
introduced into the thyA gene of Escherichia coli.56 The pFAR4-
CMV SB100X SV40 (pFAR-SB100X) miniplasmid was obtained after
extraction of the hyperactive SB100X transposase expression cassette
from pCMV(CAT)T7-SB100X40 and introduction into the antibiotic-
free pFAR4 vector.56 The PEDF-encoding transposon miniplasmid,
pFAR4-ITRs CMV PEDF BGH (pFAR-PEDF), contains ITR se-
quences amplified from pT2/HB (a gift from Perry Hackett, Addgene
plasmid #26556), a human PEDF cDNA that was generated from
ARPE-19 cells (ATCC CRL-2302) and regulatory sequences ampli-
fied from pT2-CMV-PEDF/EGFP.25 The optimized PEDF DNA308 Molecular Therapy: Nucleic Acids Vol. 6 March 2017sequence was synthesized and used to generate pFAR4-ITRs
CMV PEDFoptimized BGH (pFAR-PEDFo). The pFAR-PEDF and
pFAR-PEDFo miniplasmids have exactly the same size.
All pFAR4derivativeswere constructed andpropagatedusing thededi-
cated bacterial strain (TM#47-9a).56Miniplasmids were purified using
EndoFree plasmid preparation kits (Macherey-Nagel) and a bacterial
growth medium that meets the requirements for use in clinical trials.
Optimization of the PEDF cDNA Sequence by Reduction of ESE
Motifs
An algorithm was implemented, in which synonymous sites
embedded in ESE motifs were identified and recoded to decrease pu-
rine content, potentially increasing RNA stability. A set of 238 human
ESE motifs was employed from the RESCUE-ESE set.57 ESE motifs
are very rich in the nucleotide A (50% of all sites in ESEs), followed
by the nucleotide G with about 25% of all sites, whereas the nucleo-
tides C and T each occupying about 12%–13% of all sites. ESE motifs
were matched in all possible frames and synonymous sites identified
in the human PEDF gene. All representations of codons within the
ESE motifs for leucine were set to CTT and for arginine to CGT. At
4-fold degenerate sites embedded in ESE motifs, the C-ending codon
was preferred. At 2-fold degenerate sites A was replaced with G, C
with T, and T with C, whereas G remained unchanged. The C to T
swap is necessary to break ESE motifs. Stop codons were avoided.
The optimization program can be run iteratively until an equilibrium
density of ESE motifs is reached or stopped prior to equilibrium to
preserve a higher ESE density.
Isolation and Cultivation of Primary Human Retinal Pigment
Epithelial Cells
Human eyes from 29 donors (age 66.1 ± 13.8 years; 16 males and 13
females) were obtained from the Aachen Cornea Bank of the
Figure 5. ELISA Quantification of Total PEDF
Secretion by PEDF-Transfected Primary Human
RPE Cells
For each donor sample, two control transfections without
the addition of miniplasmid DNA and two transfections
using 0.03 mg pFAR4-CMV SB100X SV40 transposase
and 0.47 mg pFAR4-ITRs CMV PEDF BGH or pFAR4-
ITRs CMV PEDFoptimized BGH miniplasmid DNA were
carried out. Culture supernatants were analyzed 3 weeks
after transfection. (A) PEDF secretion for 1  104 cells
transfected with pFAR-PEDF was analyzed in 27 human
donor eyes (age: 67.8 ± 11.9 years; gender: 13males and
14 females; postmortem time: 31.5 ± 14.2 hr; cultivation
time before transfection: 43.0 ± 15.1 days). For 1  104
cells transfected with pFAR-PEDFo, PEDF secretion was
analyzed in 12 human donor eyes (age: 63.8 ± 13.5 years; gender: six males and six females; postmortem time: 33.0 ± 16.8 hr; cultivation time before transfection: 39.7 ±
17.8 days). (B) For 5  103 cells transfected with pFAR-PEDF, PEDF secretion was analyzed in 23 human donor eyes (age: 65.7 ± 14.7 years; gender: 13 males and ten
females; postmortem time: 32.9 ± 14.8 hr; cultivation time before transfection: 44.4 ± 15.7 days); for cells transfected with pFAR-PEDFo, PEDF secretion was analyzed in 13
human donor eyes (age: 61.1 ± 16.3 years; gender: eight males and five females; postmortem time: 32.5 ± 16.1 hr; cultivation time before transfection: 42.6 ± 18.6 days).
Data are presented as mean ± SD. Total PEDF secretion of PEDF-transfected and PEDFo-transfected cells was compared to the respective control cells (p < 0.0001,
unpaired two-tailed t test) and total PEDF secretion of PEDF-transfected cells was compared to total PEDF secretion of PEDFo-transfected cells (not significant for 1  104
cells and 5  103 cells, unpaired two-tailed t test).
www.moleculartherapy.orgDepartment of Ophthalmology, University Hospital RWTH Aachen.
The eyes were removed 31.8 ± 13.7 hr postmortem after informed
consent was obtained in accord with the Declaration of Helsinki pro-
tocols. Procedures for the collection and use of human samples were
approved by the institutional ethics committee. For RPE cell isolation,
the anterior segment was removed by a circumferential cut approxi-
mately 3 mm posterior to the limbus. After careful removal of the
vitreous and the retina, the posterior eyecup was filled with 1 mL
DMEM/Ham’s F-12 (Biochrom) supplemented with 10% FBS
(PAA Laboratories), 80 U/mL penicillin and 80 mg/mL streptomycin
(Lonza), and 2.5 mg/mL amphotericin B (Sigma-Aldrich). The cells
were harvested by gently brushing the retinal pigment epithelium
with a fire-polished glass spatula. The procedure was repeated once,
and the cell mixture was centrifuged at 1,000 rpm for 10 min. The
cell pellet from each eye was suspended in DMEM/Ham’s F-12 sup-
plemented with 10% FBS, 80 U/mL penicillin, 80 mg/mL strepto-
mycin, and 2.5 mg/mL amphotericin B and plated into three wells
of a 24-well tissue culture plate. Cultures were maintained at 37C
in a humidified atmosphere of 95% air and 5% CO2 until confluence
was reached. Cell-culture medium was changed twice a week.
Isolation and Cultivation of Primary Bovine Iris Pigment
Epithelial Cells
Bovine eyes were obtained from a local abattoir and brought to the
laboratory within 3 hr of sacrifice. The anterior segment was cut
approximately 3.5 mm posterior to the limbus and the iris was
dissected from the ciliary body. After incubation of the iris in
0.25% trypsin (GE Healthcare Europe) for 20 min at 37C, IPE cells
were isolated by gently brushing the posterior iris surface with a fire-
polished glass spatula. The detached cells were centrifuged at
1,000 rpm for 10 min, and the cell pellet was suspended in DMEM/
Ham’s F-12 supplemented with 10% FBS, 80 U/mL penicillin,
80 mg/mL streptomycin, and 2.5 mg/mL amphotericin B and platedat a density of 1  105 cells/cm2 in a 6-well tissue culture plate. The
cultures were maintained at 37C in a humidified atmosphere of
95% air and 5% CO2 until confluence was reached. Cell-culture me-
dium was changed twice a week.
Electroporation of Primary Pigment Epithelial Cells and
Cultivation of the Transfected Cells
Transfections were performed with the Neon Transfection System
using the 10 mL Kit (Life Technologies) according to the manufac-
turer’s protocol. The electroporation parameters were as follows:
two pulses, 1,100 V (pulse voltage), 20 ms (pulse width). 1  104
or 5  103 cells in 11 mL resuspension buffer R (Life Technologies)
were combined with 2 mL of purified plasmid mixture containing
0.03 mg pFAR-SB100X transposase and 0.47 mg pFAR-PEDF or
0.47 mg pFAR-PEDFo transposon. Each experiment comprised eight
transfection controls without electrical field application and without
miniplasmid DNA, six transfection controls with electrical field
application without miniplasmid DNA, and 12 transfections with
electrical field application and miniplasmid DNA for each trans-
poson miniplasmid. Transfected cells were transferred into 48-well
tissue culture plates containing 0.5 mL of DMEM/Ham’s F-12 sup-
plemented with 10% FBS, without antibiotics and antimycotics. Peni-
cillin (80 U/mL), streptomycin (80 mg/mL), and amphotericin B
(2.5 mg/mL) were added with the first medium exchange 3 days after
electroporation. Cell cultures were either used after 3 weeks for
further analyses or maintained for the analysis of long-term PEDF
secretion.
SDS-PAGE and Western Blot Analysis
For SDS-PAGE, 15 mL of culture supernatant was mixed with an
equal volume of 2  SDS sample buffer58 and heated for 5 min at
95C. Proteins were separated on a 10% SDS-PAGE gel and trans-
ferred onto a 0.45-mmpore-size nitrocellulose membrane (Whatman)Molecular Therapy: Nucleic Acids Vol. 6 March 2017 309
Figure 6. Western-Blot-Based Quantification of
Long-Term PEDF Secretion in Primary Human RPE
Cells after SB100X-Mediated Transfection
For each donor sample, two control transfections without
the addition of miniplasmid DNA and two transfections
using 0.03 mg pFAR4-CMV SB100X SV40 transposase
and 0.47 mg pFAR4-ITRs CMV PEDF BGH or pFAR4-
ITRs CMV PEDFoptimized BGH miniplasmid DNA were
carried out. Culture supernatants were analyzed for total
PEDF secretion every 4–8 weeks. Western blot signal
intensities of PEDF-transfected and PEDFo-transfected
cells were normalized to the signal intensities of the
control cells. Data are presented as mean ± SD. Mean
signal intensities of PEDF secretion 21 days after trans-
fection are indicated by the dashed line. (A) For 1  104
cells, PEDF secretion was analyzed for 215 ± 20 days for
pFAR-PEDF-transfected cells and for 193 days for pFAR-
PEDFo-transfected cells. (B) For 5  103 cells, PEDF
secretion was analyzed for 216 ± 20 days for pFAR-
PEDF-transfected cells and for 201 ± 11 days for pFAR-
PEDFo-transfected cells. Statistical analysis using an
unpaired two-tailed t test showed a significant difference
between transfected cells and non-transfected control
cells. A comparison of PEDF-transfected cells to PEDFo-
transfected cells showed no significant difference in PEDF
secretion for 110 days, but by 160 days, a significant
decrease in PEDF secretion by pFAR-PEDF-transfected
cells compared to pFAR-PEDFo-transfected cells was
observed.
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staining to confirm the transfer. For the detection of total (endoge-
nous plus recombinant) PEDF, blots were blocked with 3% BSA/
Tris-buffered saline (TBS) for 2 hr at room temperature and incu-
bated for 1 hr at room temperature and overnight at 4C with anti-
PEDF antibodies (rabbit polyclonal; 1:4,000 diluted in 3% BSA/
TBS; BioProducts MD), followed by incubation for 1 hr at room tem-
perature with horseradish peroxidase-conjugated anti-rabbit anti-
bodies (goat polyclonal; 1:2,000 diluted in 10% milk powder/TBS;
Abcam). Proteins bands were visualized by chemiluminescence using
the LAS-3000 imaging system (Fujifilm) or the Omega Lum G
Imaging System (Aplegen) and evaluated by the open source image
processing program ImageJ (Rasband, W.S., ImageJ, U.S. NIH,
http://imagej.nih.gov/ij/, 1997–2014).ELISA-Based Quantification of Total PEDF Secretion
Total PEDF secretion was analyzed in culture supernatants of control
and PEDF-transfected cells 3–4 weeks after transfection. Cells were
incubated in a defined volume of 0.5 mL cell-culture medium.
After 24 hr, the culture media were analyzed by ELISA for human
PEDF using the ELISAquant kit (BioProducts MD) according to
the manufacturer’s protocol. Secreted PEDF was related to the cell
number determined in each well. Cells were trypsinized with 0.05%
trypsin-0.02% EDTA (PAA Laboratories) and counted using a310 Molecular Therapy: Nucleic Acids Vol. 6 March 2017Neubauer chamber or the CASY Cell Counter Model TT (Roche
Diagnostics).Isolation of Total RNA and Genomic DNA
Total RNA was isolated using the RNeasy Mini Kit together with the
RNase-free DNase Set (QIAGEN) according to the manufacturer’s
protocol. Reverse transcription was carried out on 0.1 mg total RNA
using the Reverse Transcription System (Promega). Genomic DNA
was isolated using the QIAamp DNA Mini Kit (QIAGEN) according
to the manufacturer’s protocol for cultured cells.Real-Time qPCR
For human RPE cells, real-time qPCRs were performed on a
LightCycler 1.2 Instrument using the LightCycler FastStart DNA
Master SYBR Green I kit (Roche) according to the manufacturer’s
recommendations. The cDNA samples were run in duplicate using
the following primers: GAPDH (GenBank: NM_002046.3) as the in-
ternal control gene (F: 50-ATC CCA TCA CCA TCT TCC AG-30 and
R: 50-ATG AGT CCT TCC ACG ATA CC-30), endogenous PEDF
(GenBank: NM_002615.4) (F: 50-GCT GGC TTT GAG TGG AAC
GA-30 and R: 50-GTG TCC TGT GGAATC TGC TG-30), and endog-
enous plus recombinant PEDF (F: 50-CCT GCA GGA GAT GAA
GCT GCA-30 and R: 50-TCC ACC TGA GTC AGC TTG ATG-30),
for the detection of the endogenous PEDF gene plus the PEDF and
Figure 7. Integration Profiling of the pFAR4-ITRs
CMV PEDF BGH Transposon in Human RPE Cells
(A) Consensus sequence of the Sleeping Beauty insertion
sites. The y axis in the Seqlogo analysis represents the
strength of the information, with two bits being the
maximum for a DNA sequence. (B) SB integration sites in
human RPE cells were compared to a random control set
of 1  104 computationally generated loci, determining
the frequencies of integrations into annotated genomic
features including 30 UTRs, 50 UTRs, exons, introns, gene
bodies, and regions around transcription start sites. The
integration profile was found to be close-to-random.
(C) Relative frequencies of SB insertions into chromo-
somal sites defined as genomic safe harbors in compar-
ison with the random dataset. (D) Relative frequency of
SB integrations into genomic safe harbors, cumulative for
all five subcategories shown in (C), in comparison with the
random dataset.
www.moleculartherapy.orgthe optimized PEDF genes encoded in the pFAR4 miniplasmids.
Reactions were performed with diluted cDNA corresponding to
2 ng of initially used total RNA and a primer concentration of
0.25 mM. Thermal cycler conditions were as follows: initial denatur-
ation at 95C for 10 min followed by 50 cycles with denaturation at
95C for 10 s, annealing at 60C for 8 s, and elongation at 72C for
15 s. Melting curve analysis confirmed the application specificity of
each primer pair. Data were processed by the LightCycler software
3.5.3 and evaluated using the comparative CT (2-DDCT) method,
which describes relative gene expression.59
For bovine IPE cells, real-time qPCRs were performed on a
LightCycler 480 II instrument (Roche) using PerfeCta SYBR
Green FastMix (Quanta Biosciences) according to manufacturer’s
recommendations. The cDNA samples were run in duplicate in
three independent experiments using the following primers: GAPDH
(GenBank: NM_001034034.2) as the internal control gene (F: 50-ATC
ATC CCT GCT TCT ACT GG-30 and R: 50-CTC AGT GTA GCC
TAG AAT GC-30), endogenous PEDF (GenBank: AF017058.1)
(F: 50-TTC CCT CTG GAC TAT CAC CT-30 and R: 50-AAT CTG
CCA TCC CTC TAG TG-30), and recombinant PEDF (F: 50-CCT
GCA GGA GAT GAA GCT GCA-30 and R: 50-TCC ACC TGA
GTCAGC TTGATG-30), for the detection of the PEDF transgene en-
coded in the pFAR-PEDF and pFAR-PEDFominiplasmids. Reactions
were performed with diluted cDNA corresponding to 1.2 ng of
initially used total RNA, and primer concentrations of 3.5 mM for
GAPDH and recombinant PEDF, and 1.75 mM for endogenous
PEDF. Thermal cycler conditions were as follows: initial denaturationMoleculaat 95C for 10 min followed by 45 cycles with
denaturation at 95C for 5 s, annealing at
60C for 10 s, and elongation at 72C for 10 s.
Melting curve analysis confirmed the applica-
tion specificity of each primer pair; standard
curves demonstrated high efficiency and good
reproducibility of each experiment. Data wereprocessed by the LightCycler 480 software 1.5.1.62 and evaluated
using the standard curve-based absolute quantification method. The
values were analyzed for statistical significance using a non-para-
metric Kruskal-Wallis test (GraphPad Prism, GraphPad).
Integration Site Library Construction
A computation-assisted hemi-specific PCR scheme was used to
generate the insertion site libraries. The PCR assays were based on
the use of computationally designed hemi-specific primers carrying
four specific nucleotides (4-mers) at their 30 ends followed by random
sequences and a specific overhang.60 The computational primer
design comprised: (1) choosing 4-mers that cannot give rise to un-
wanted amplicons on the transposon end or on the primer overhangs
and (2) predicting the combination of those six 4-mers, which theo-
retically would result in the most comprehensive insertion site library
on the human genome. Nested PCRs were performed to obtain in-
dexed, Illumina-flow cell compatible insertion site libraries. Primer
sequences are listed in Table S3. Following a short enrichment PCR
using 300 ng of genomic DNA as template (primer SB_20_hmr,
PCR conditions: 95C for 2 min, 50 cycles of 94C for 30 s, ramp
to 63C: 1C/s, 63C for 30 s, 72C for 30 s), six parallel PCRs/sample
were carried out, each containing 5 pmol of six different hemi-specific
4-mer primers using the following conditions: 95C for 1 min,
40 cycles of 94C for 30 s, ramp to 63C: 1C/s, 63C for 30 s,
72C for 30 s, two cycles of 94C for 30 s, 25C for 1 min and 30 s,
ramp to 72C: 0.2C/s, 72C for 1 min. Then each PCR was supple-
mented with 25 mL of PCR master mix containing 15 pmol of SB_7
primer. The PCR program for the nested PCR was: 15 super-cyclesr Therapy: Nucleic Acids Vol. 6 March 2017 311
Molecular Therapy: Nucleic Acidsof three cycles of 94C for 30 s, ramp to 64C: 1C/s, 64C for 30 s,
72C for 40 s, one cycle of 94C for 30 s, ramp to 60C: 0.5C/s,
60C for 30 s, 72C for 40 s, final extension of 72C for 5 min. The
PCR products were column-purified, and 2 mL of the 30-mL elutes
was used for the first exponential PCRs, with the primer PE_first
and SB_PE_noTA_BC_n using the following cycling conditions:
95C for 30 s, 20 cycles of 94C for 30 s, ramp to 64C: 1C/s,
64C for 30 s, 72C for 1 min, final extension 72C for 5 min. The first
exponential PCR products diluted 10-fold were used to append the
Illumina adaptors to the amplicons using Pfx polymerase (Life Tech-
nologies) with the following cycling conditions: 95C for 30 s,
20 cycles of 94C for 15 s, 68C for 1 min, final extension 68C for
5 min. The final PCR products were separated on agarose gels and
amplicons between 200 and 500 bp were excised and column purified
(Zymoclean Gel DNA Recovery Kit; Zymo Research). Sequencing of
the resulting libraries was carried out on an Illumina HiSeq 2500 in-
strument with rapid run flow-cells at the Beckman Coulter Genomics
sequencing facility.Computational Analysis
The raw reads were processed for mapping using R (R: A language
and environment for statistical computing; R Foundation for Statis-
tical Computing, https://www.r-project.org/) as follows: primer-,
transposon-, and right Illumina adaptor-related sequences were
trimmed and the resulting reads were quality filtered by omitting
reads containing “N” bases and by trimming reads as soon as two
of five bases have quality encoding less than a phred score of 20.
All trimmed reads shorter than 24 bases were not included in
further analysis. The remaining sequences were mapped against
the hg19 human genome assembly with Bowtie.61 We identified
3,114 independent integration events from three different human
RPE samples for the pFAR4-ITRs CMV PEDF BGH transposon.
Reads mapped to exactly the same strand and genomic positions
were merged to a single site. To improve data quality, we discarded
all sites supported by less than ten reads. The sequence logos for the
nucleotide composition around the integration sites were generated
with the seqLogo package in R. To compute the representation of
the insertion sites in various annotated segments of the human
genome, databases for various genomic features were downloaded
from the UCSC database (http://genome.ucsc.edu), and the repre-
sentation of the insertion sites were counted in the feature intervals
using the BEDTools suite.62 A set of 10,000 computationally gener-
ated random genomic loci of the human genome was used as a
reference.Statistical Analysis
Unless otherwise stated, statistical analysis was performed using an
unpaired two-tailed t test (GraphPad Prism, GraphPad).SUPPLEMENTAL INFORMATION
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